Source: Annual Congress 2006 - Pulmonary hypertension: thromo-embolic processes
Disease area: Pulmonary vascular diseases

Abstract

Study objective: To evaluate the effects of inhaled nitric oxide (iNO) on pulmonary hemodynamics and gas exchange in patients with CTEPH.
Methods: Ten patients with CTEPH were included into the study (8 males; mean age: 62.4±9.4 yrs; mean pulmonary artery pressure (Ppa) 45.7±7.5 mmHg; mean DLCO 76±15%). Oxygenation and hemodynamic variables were measured and calculated at baseline and then 30 min after each sequential addition of 10, 20, and 40 ppm iNO.
Results: There was no improvement in Ppa during inhalation of iNO (10 ppm iNO: 45.0±10.2 mmHg; 20 ppm iNO: 44.7±7.4 mmHg; 40 ppm iNO: 44.0±8.7 mmHg), but statistically significant and dose-dependent increase in stroke volume was observed (baseline: 62.1±6.6 ml; 10 ppm iNO: 71.4±23 ml; 20 ppm iNO: 74.1 ± 27.3 ml; 40 ppm iNO: 77.4 ± 25.4 ml (all p<0,01). There also was a mild but significant improvement in oxygenation at 20 ppm iNO (SaO₂ increased from 85.8±6.6% to 90.0±4.6%, p<0.05).
Conclusion: iNO does not decrease pulmonary pressures in patients with chronic thromboembolic pulmonary hypertension, but has a small positive effects on stroke volume and oxygenation variables.

Rating:

Share or cite this content

Citations should be made in the following way:
N. Tsareva, S. Avdeev, G. Nekludova, A. Chuchalin (Moscow, Russian Federation). Inhaled nitric oxide in patients with chronic thromboembolic pulmonary hypertension (CTEPH). Eur Respir J 2006; 28: Suppl. 50, 2354

Member's Comments

No comment yet.

Related content which might interest you: Exhaled nitric oxide in patients with idiopathic pulmonary fibrosis and pulmonary hypertension Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008 Nitric oxide in acute testing in patients with pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 277s Year: 2004 Measurement of gas transfer components using nitric oxide in post pulmonary endartectomy (PEA) chronic thromboembolic hypertension (CTEPH) patients Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012 Acute vasoresponsiveness to inhaled nitric oxide in sarcoidosis-associated pulmonary hypertension Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008 Nitric oxide vs prostacyclin in chronic high-flow pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 24s Year: 2002 Vasoreactivity to inhaled nitric oxide does not predict long term survival in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016 Inhaled nitric oxide (NO) for vasoreactivity testing in pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 584s Year: 2003 Nitric oxide and oxygen inhalation during exercise in patients with chronic obstructive lung disease (COPD) and secondary pulmonary hypertension (PH) Source: Eur Respir J 2001; 18: Suppl. 33, 83s Year: 2001 Profiling nitric oxide metabolites in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2016; 48: 1386-1395 Year: 2016 Inhaled nitric oxide (iNO) in patients with acute cor pulmonale due to acute exacerbation of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 269s Year: 2003 The effect of inhaled nitric oxide on the cardiac performance in patients with hypoxic pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 269s Year: 2003 Effect of the Asp298 variant of endothelial nitric oxide synthase on acute pulmonary vasodilator testing response in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 547s Year: 2006 Fractional exhaled nitric oxide in patients with chronic obstructive pulmonary disease Source: International Congress 2019 – FeNO in airway diseases and asthma-COPD overlap identification Year: 2019 Infused nitric oxide in experimental pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 348s Year: 2007 Tolerance of long term nitric oxide treatment in severe arterial pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 370s Year: 2002 Exhaled nitric oxide levels in patients with pulmonary hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Comparison of hemodynamic effects of inhaled nitric oxide (iNO) and inhaled epoprostenol (iEPO) in patients with pulmonary hypertension (PH) Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Pulmonary hypertension in patients with COPD Source: Eur Respir Mon 2012; 57: 138-147 Year: 2012 Nitric oxide in the COPD pathogenesis in patients with pulmonary tuberculosis Source: International Congress 2019 – Oxidative stress, hypoxia and microbial exposure in the pathogenesis of pulmonary disease Year: 2019 The acute haemodynamic effects of 'pulsed' inhaled nitric oxide and iv epoprostenol in patients with pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 584s Year: 2003